Insulin is a Gift of Life for People With Diabetes
DOI:
https://doi.org/10.17140/DROJ-1-106Keywords:
Diabetes Diabetes Mellitus, Insulin Pancreatic beta cells, Postprandial blood glucose, Fasting blood glucose, Glycosylated haemoglobin, Gift of life Diabetic complicationsAbstract
Although Diabetes Mellitus (DM) or sugar diabetes was identified centuries ago, it was not known why this metabolic disorder develops until JR Macleod and Frederick Banting made the discovery. DM is due to deficiency of insulin produced by beta cells of the pancreas. Prior to this discovery and its application around 1921, many people with this disorder died from diabetic coma. Thus insulin made a milestone in the treatment of DM, in early part of the 20th century and it is the same today. However, commercialism prevails in the care of DM with too much twist in the therapy. It is now the norm to prescribe oral anti-diabetic agents in all adults with diabetes called Type 2 DM. Oral anti-diabetic drugs lower fasting blood glucose and HbA1c but not 2h postprandial blood glucose. The latter is related to diabetic complications. Thus, although patients are not dying from diabetic coma because of insulin but they are
developing whole gamut of complications which have increased the morbidity and mortality in patients with DM. Thus the emphasis of this article is to resurge the use of insulin as a gift of life for patients with DM and a therapy which permits a healthy and active life for them.
References
Banting FG. Nobel Prize speech September 15, 1925 In His-tory of Diabetes Mellitus Elsevier Masson. 2009; 49-62.
Mandal AK, Puchalski JT, Lemley-Gillespie S, Taylor CA, Kohno M. Effect of insulin and heparin on glucose-induced vas-cular damage in cell culture. Kidney Int. 2000; 57: 2492-2501. doi: 10.1046/j.1523-1755.2000.00108.x
Fabre J, Balant LP, Dayer PG, Fox HM, Vernet AT. Kidney in mature onset diabetes mellitus: a clinical study of 510 patients. Kidney Int. 1982; 21: 730-738. doi: 10.1038/ki.1982.90
Mandal AK. Frequent office visits of patients with chronic kidney disease: Is a prelude to prevention of dialysis. World J Nephrology. 2014; 3: 1-5. doi: 10.5527/wjn.v3.i1.1
Saydah SH, Miret M, Sung J, Varas C, Gause O, Brancate FL. Post challenge hyperglycemia and mortality in national sample of US adults. Diab Care. 2001: 26: 1397-1402. doi: 10.2337/ diacare.24.8.1397
Gerich JE Clinical significance, pathogenesis and manage-ment of postprandial hyperglycemia. Arch Intern Med. 2003; 163: 1306-1316. doi: 10.1001/archinte.163.11.1306
Heller SR, Amiel SA, Mansell F, UK Lispro study Group. Effect of fast acting insulin analog lispro on the risk of noctur-nal hypoglycemia during intensified insulin therapy. Diab Care. 1999; 22: 1607-1611. doi: 10.2337/diacare.22.10.1607
Mandal AK Prevailing commercialism in diabetes care, is the road to diabetic complication. J Autoimmunity and research. 2014; 1: 1002.
Hamaty M. Insulin treatment for Type 2 diabetes: when to start and which to use Clevclin. J Med. 2011; 78: 332-342.
Mandal AK, Ping T, Coldwell SJ, Bagnell R, Hiebert LM. Electron microscopic analysis of glucose-induced endothelial damage in primary cell culture: Possible mechanism and preven-tion. Histology and Histopathology. 2006; 21: 941-950.
Brownlee M. Pathobiology of diabetic complications. Diabe-tes. 2005; 54: 1615-1625. doi: 10.2337/diabetes.54.6.1615
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Diabetes Research (DR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
